KOLDexmethylphenidate
Who are the top experts researching the use of Dexmethylphenidate?
The top experts researching Dexmethylphenidate are: Rafael Muniz, John Giblin and David Sugrue.
What are the top concepts researched in studies about Dexmethylphenidate?
The most researched concepts in studies of Dexmethylphenidate are: Hyperactivity Disorder, Attention Deficit, Extended Release and Adhd Symptoms.
Recent articles about Dexmethylphenidate
A Randomized, Double-Blind, Crossover Study Of Once-Daily Dexmethylphenidate In...
.. of dexmethylphenidate extended release (ER) versus placebo by measuring the change from pre-dose to 0.5 hours post-dose on the Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP) rating ...
Known for Hyperactivity Disorder | Crossover Study | Daily Dexmethylphenidate | Post Dose | Laboratory Classroom Efficacy And Safety Of Dexmethylphenidate Extended-Release Capsules In Adults...
.. extended-release dexmethylphenidate (d-MPH-ER) in adults with attention-deficit/hyperactivity disorder (ADHD).
METHODS: Randomized adults with ADHD (n=221) received once-daily d-MPH-ER 20 ...
Known for Hyperactivity Disorder | Adults Adhd | Dexmethylphenidate Extended | Illness Surveys | Total Score Long-Term Effectiveness And Safety Of Dexmethylphenidate Extended-Release...
.. evaluates dexmethylphenidate extended release (d-MPH-ER) in adults with ADHD.
METHOD: Following a 5-week, randomized, controlled, fixed-dose study of d-MPH-ER 20 to 40 mg/d, 170 adults ...
Known for Adult Adhd | Dexmethylphenidate Extended | Mph 20 | Longterm Safety | Term Treatment Differential Influences Of Ethanol On Early Exposure To Racemic Methylphenidate...
.. isomer dexmethylphenidate (d-MPH) will overcome the influence of ethanol on d-MPH absorption by eliminating competitive CES1-mediated presystemic metabolism of l-MPH to l-EPH. Twenty-four hea
Known for Mph Ethanol | Early Exposure | Plasma Concentrations | Subjective Effects | Adult Area Open-Label Study Of Dexmethylphenidate Hydrochloride In Children And Adolescents...
.. of dexmethylphenidate (d-MPH) given once-daily in subjects with attention deficit hyperactivity disorder (ADHD).
METHOD: Subjects aged 6-18 years (inclusive) with ADHD were enrolled in ...
Known for Dexmethylphenidate Hydrochloride | Attention Deficit | Hyperactivity Disorder | Adhd Children | Rating Scales Extended-Release Dexmethylphenidate 30 Mg/d Versus 20 Mg/d
.. of dexmethylphenidate (D-MPH) extended-release (ER) 30 mg and D-MPH-ER 20 mg on attention, behavior, and performance in children with attention-deficit/hyperactivity disorder.
METHODS: In ...
Known for Attention Deficit | Hyperactivity Disorder | Dexmethylphenidate Mph | Nervous Stimulants | Rating Scale Testing Tic Suppression: Comparing The Effects Of Dexmethylphenidate To No...
.. immediate-release dexmethylphenidate (dMPH) can facilitate tic suppression in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and Tourette's disorder (TD) or ...
Known for Tic Suppression | Children Adhd | Hyperactivity Disorder | Attention Deficit | Tourette Syndrome Dexmethylphenidate Hydrochloride In The Treatment Of Attention Deficit...
.. ADHD. Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-(R,R)-MPH, was recently introduced as another potential option in the stimulant class of ...
Known for Attention Deficit | Hyperactivity Disorder | Dexmethylphenidate | Adhd | Stimulants Dexmethylphenidate Extended Release
.. Abstract▴ Dexmethylphenidate extended release (XR) is an orally administered, bimodal release, capsule formulation of the active d-enantiomer of methylphenidate (MPH), which inhibits ...
Known for Dexmethylphenidate Xr Children | Adolescents Adults | Extended Release | Hyperactivity Disorder | Attention Deficit Dexmethylphenidate
.. Abstract▴ Dexmethylphenidate comprises only the d-enantiomer (the pharmacologically effective isomer) of racemic methylphenidate and is indicated for the treatment of patients aged ≥6 ...
Known for ▴ Dexmethylphenidate | Methylphenidate Treatment | Children Adhd | Placebo Recipients | Hyperactivity Disorder